Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to $121.7 million.

  • Guardian Pharmacy Services' Accounts Payables rose 1385.33% to $121.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 1385.33%. This contributed to the annual value of $102.4 million for FY2024, which is 1964.53% up from last year.
  • Guardian Pharmacy Services' Accounts Payables amounted to $121.7 million in Q3 2025, which was up 1385.33% from $105.0 million recorded in Q2 2025.
  • In the past 5 years, Guardian Pharmacy Services' Accounts Payables ranged from a high of $121.7 million in Q3 2025 and a low of $85.6 million during Q4 2023
  • Moreover, its 3-year median value for Accounts Payables was $103.7 million (2024), whereas its average is $103.9 million.
  • As far as peak fluctuations go, Guardian Pharmacy Services' Accounts Payables skyrocketed by 1964.53% in 2024, and later soared by 1385.33% in 2025.
  • Quarter analysis of 3 years shows Guardian Pharmacy Services' Accounts Payables stood at $85.6 million in 2023, then grew by 19.65% to $102.4 million in 2024, then rose by 18.8% to $121.7 million in 2025.
  • Its Accounts Payables was $121.7 million in Q3 2025, compared to $105.0 million in Q2 2025 and $101.7 million in Q1 2025.